Company intelligence / Profile preview
LongBio Pharma
Shanghai, Shanghai, Chinalongbio.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 3
01
Overview
LP-003 (anti-IgE antibody) is in Phase III and preparing for pre-BLA in 2025H2. It has shown superior improvement compared to Omalizumab in CSU Phase II trials. LP-005 (bifunctional complement inhibitor) is in Phase II for PNH. LP-001 is in Phase I for anemia.
- Therapeutic areas
- PulmonologyNephrologyOphthalmologyImmunologyDermatologyHematologyNeurology
- Modalities
- AntibodiesFusion proteinsBiologics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on LongBio Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LongBio Pharma.